Literature DB >> 24102870

Correlation between myocardial fibrosis and restrictive cardiac physiology in patients undergoing retransplantation.

Jon A Kobashigawa1, Brandon K Itagaki, Rabia R Razi, Jignesh K Patel, Wanxing Chai, Matthew A Kawano, Zachary Goldstein, Michelle M Kittleson, Michael C Fishbein.   

Abstract

After cardiac transplant, there is often development of restrictive cardiac physiology. Little is known about the factors that contribute to this physiology and its correlation with pathology. Heart retransplantation provides a valuable opportunity to further understand this relationship. In this study, we investigated the correlation of myocardial fibrosis and restrictive physiology, and possible risk factors utilizing data from all retransplants at our center. A retrospective review of the 30 patients who underwent retransplantation at our institution between 1994 and 2004 was performed. Hemodynamic and imaging data were reviewed for the presence of restrictive physiology. Pathology reports were reviewed for the presence of myocardial fibrosis in the explanted hearts. The cohort with restrictive physiology preceding redo heart transplant had significantly more patients exhibiting myocardial fibrosis compared with the non-restrictive physiology group (94.1% vs. 15.4%, p < 0.001). We found no difference in the immunosuppressive regimen, history of rejection, and reason for transplant. In our study, we observed that myocardial fibrosis is an important contributor to the development of restrictive physiology. Further work needs to be done for risk stratification and the mechanism of fibrosis development.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cardiac allograft vasculopathy; inflammation; myocardial fibrosis; restrictive cardiac physiology; retransplantation

Mesh:

Year:  2013        PMID: 24102870     DOI: 10.1111/ctr.12250

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  7 in total

1.  Myocardial Fibrosis and Prognosis in Heart Transplant Recipients.

Authors:  Andrew Hughes; Osama Okasha; Afshin Farzaneh-Far; Felipe Kazmirczak; Prabhjot S Nijjar; Pratik Velangi; Mehmet Akçakaya; Cindy M Martin; Chetan Shenoy
Journal:  Circ Cardiovasc Imaging       Date:  2019-10-15       Impact factor: 7.792

Review 2.  Outcomes following cardiac transplantation in adults.

Authors:  Sai Bhagra; Jayan Parameshwar
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2019-02-15

3.  International Society of Heart and Lung Transplantation position statement on the role of right heart catheterization in the management of heart transplant recipients.

Authors:  Hoong Sern Lim; Eileen Hsich; Keyur B Shah
Journal:  J Heart Lung Transplant       Date:  2018-12-21       Impact factor: 10.247

4.  De novo expression of fetal ED-A(+) fibronectin and B (+) tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection.

Authors:  Marcus Franz; Monika Matusiak-Brückner; Petra Richter; Katja Grün; Barbara Ziffels; Dario Neri; Hansjörg Maschek; Uwe Schulz; Alexander Pfeil; Christian Jung; Hans R Figulla; Jan Gummert; Alexander Berndt; André Renner
Journal:  J Mol Histol       Date:  2014-05-03       Impact factor: 2.611

5.  Histological validation of cardiovascular magnetic resonance T1 mapping markers of myocardial fibrosis in paediatric heart transplant recipients.

Authors:  Seiko Ide; Eugenie Riesenkampff; David A Chiasson; Anne I Dipchand; Paul F Kantor; Rajiv R Chaturvedi; Shi-Joon Yoo; Lars Grosse-Wortmann
Journal:  J Cardiovasc Magn Reson       Date:  2017-02-01       Impact factor: 5.364

6.  Impact of Sirolimus as a Primary Immunosuppressant on Myocardial Fibrosis and Diastolic Function Following Heart Transplantation.

Authors:  Hilmi Alnsasra; Rabea Asleh; Jae K Oh; Joseph J Maleszewski; Amir Lerman; Takumi Toya; Krishnaswamy Chandrasekaran; Melanie C Bois; Sudhir S Kushwaha
Journal:  J Am Heart Assoc       Date:  2020-12-16       Impact factor: 5.501

7.  Native T1 mapping detects both acute clinical rejection and graft dysfunction in pediatric heart transplant patients.

Authors:  Devika P Richmann; Nyshidha Gurijala; Jason G Mandell; Ashish Doshi; Karin Hamman; Christopher Rossi; Avi Z Rosenberg; Russell Cross; Joshua Kanter; John T Berger; Laura Olivieri
Journal:  J Cardiovasc Magn Reson       Date:  2022-10-03       Impact factor: 6.903

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.